Background/Aims: The purpose of the study was to investigate the altered driver genes and signal pathways during progression of papillary thyroid cancer (PTC) via next-generation sequencing technology. Methods: The DNA samples for whole exome sequencing (WES) analyses were extracted from 11 PTC tissues and adjacent normal tissues samples. Direct Sanger sequencing was applied to validate the identified mutations. Results: Among the 11 pairs of tissues specimens, 299 single nucleotide variants (SNVs) in 75 genes were identified. The most common pattern of base pair substitutions was T:A>C:G (49.83%), followed by C:G>T:A (18.06%) and C:G>G:C (15.05%). The altered genes were mainly implicated in MAPK (mitogen-activated protein kinase), PPAR (peroxisome proliferator-activated receptors), and p53 signaling pathways. In addition, 12 novel identified driver genes were validated by Sanger sequencing. The mutations of FAM133A, DPCR1, JAK1, C10orf10, EPB41L3, GPRASP1 and IWS1 exhibited in multiple PTC cases. Furthermore, the PTC cases exhibited individual mutational signature, even the same gene might present different mutational status in different cases. Conclusion: Multiple PTC-related somatic mutations and signal pathways are identified via WES and Sanger sequencing methods. The novel identified mutations in genes such as FAM133A, DPCR1, and JAK1 may be potential therapeutic targets for PTC patients.
Introduction
Thyroid cancer is a common endocrine malignancy, with rapidly increased morbidity during the last few decades [1] . The incidence rate of thyroid cancer presents distinct age and gender diversities, and its morbidity is significantly higher in women than that in men [2] . Papillary thyroid carcinoma (PTC) represents the most common histological subtype of thyroid cancer, accounting for about 75-85% of the cases [3] . Until now, surgical strategy is the major treatment for patients with thyroid cancer, due to its high resistance to standard chemotherapy [4] . However, the extensive resection, postoperative recurrence and metastasis may lead to limited therapeutic effects and poor outcomes [5] . The reliable tools are urgently needed to predict tumor progression and prognosis for patients with PTC. PTC is a complex disease, and both genetic and environmental factors such as iodine intake and radiation exposure are implicated in etiology of the cancer [6, 7] . Growing evidences have demonstrated that genetic factors play an important role in PTC development and treatments [8, 9] . Until now the mechanisms underlying the tumorigenesis of PTC still remains unclear, and prediction of disease progression is a great challenge for PTC cases [10] .
Recent progress in sequencing techniques may provide a promising way to identify the somatic mutations and altered signal pathways during progression of PTC. Whole exome sequencing (WES) is an effective technology to identify the mutations in the exome regions using the next-generation sequencing, becoming a commonly used approach to investigate the genetic alteration in diseases, like cancer [11] . In the previous investigations, the success application of WES was reported in various cancers. For example, Li et al. performed WES combined with genome sequencing method on Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (NPC) tissues specimens, and they observed the mutations of multiple negative regulators in NF-κB pathway such as CYLD, TRAF3, NFKBIA and NLRC5, suggesting the functional roles of NF-κB pathway in tumorigenesis of NPC [12] . Guo and colleagues identified 54 single nucleotide polymorphisms (SNPs) and 41 indels of prominent variations in solid pseudopapillary tumor of the pancreas, revealing their involvements in molecular mechanism of the cancer [13] . The application of WES in thyroid cancer was also reported in the previous tumor researches. Lu et al. observed that the mutations status of driver genes were significantly different among patients with multifocal papillary thyroid cancer (MPTC) via WES and targeted region sequencing methods [14] . Based on the related researches, we speculated that WES might be a promising approach to identify the mutational genes and pathways in progression of PTC, which might provide a new insight into the etiology of the malignant disease.
In this study, we performed WES combined with Sanger sequencing technology to investigate the profile of genetic alterations in 11 PTC cases. The genetic mutations and altered pathways during progression of PTC were characterized in order to explore novel PTC-related genes which might be applied for individual treatments of PTC.
Materials and Methods

Study population and specimens collection
In the current study, PTC tissues and adjacent normal tissues specimens were collected from 11 patients who underwent thyroid surgery in 307 hospital, PLA. The tissues samples were immediately frozen in liquid nitrogen, and then stored at -80°C for further analyses. All of the patients were pathologically diagnosed with PTC according to World Health Organization classification, and the tissues specimens were reviewed by two pathologists. In addition, fasting blood specimens were also collected from the patients before surgeries to serve as control. None of the patients had received radioactive iodine treatment or other therapies before samples collection. The baseline characteristics of the patients were collected from the clinical records and summarized in Table 1 . The study protocols were approved by the Ethic Committee of the hospital. All the patients or their family signed the informed consents in advance. was applied to purify the DNA fragments. Subsequently, the adaptors were ligated to the fragments at both ends. The Agecoure AMPure SPRI beads (Beckmancoulter, Brea, CA, USA) was performed to purify the adapter-ligated templates. For enrichment, the DNA fragments were amplified by ligated-mediated PCR amplification system according to the Illumina's suggesting protocols (Illumina, San Diego, CA). After amplification and purification, the quality of the libraries was detected by Agilent 2100 Bioanalyzer (Agilent Technologies, San Jose, CA, USA).
Exome capture and sequencing
Exome was captured by Agilent SureSelect paired-end version 2.0 human exome kit (Agilent, Santa Clara, CA) following the instruction of the manufactures. Then Illumina HiSeq2000 Genome Analyzer platform (Illumina, San Diego, CA) was used for exome sequencing. The base calling was performed with Illumina basecalling Software 1.7, generating 100bp paired end reads.
Somatic variations validation
Sanger sequencing technique was carried out to verify the somatic mutations of interest in each diseased tissue sample. PCR reaction was performed in a 2720 Thermal Cycler (Applied Biosystems, Foster City, CA, USA) using Platinum Taq (Invitrogen, Foster City, CA, USA). After purification, the products were sequenced by Terminator v3.0 cycle sequencing reagents (Applied Biosystems, Foster City, CA, USA), and the results were analyzed on ABIPRISM 3100 automated sequencer (Applied Biosystems, Foster City, CA, USA).
Bioinformatics analyses
Illumina basecalling Software 1.7 (Illumina, San Diego, CA) was applied for base calling, generating 100bp paired end reads. The reads were then aligned to the human reference genome (UCSC hg 19) using Burrows-Wheeler Aligner method with default parameters [15] . VarScan 2 method was used to analyze somatic mutations [16] . Single nucleotide variants (SNVs) and insertions and deletions mutations were annotated by ANNOVAR tool (http://www.openbioinformatics.org/annovar/) [17, 18] . MuSiC software (http://www.broadinstitute.org/cancer/cga/mutsig) was applied to identify the significantly mutated genes, and annotate the related pathways [19] [20] [21] .
Results
Baseline characteristics of the study population A total of 11 eligible patients were recruited in the present study. Nine of the patients were females, and their average age was 42.82 ± 14.11 years. Four of the patients were diagnosed with TI stage, six patients were at TIII stage, and the remaining one patient was at TIVa stage. In addition, seven of the patients presented lymph node metastasis. The clinical characteristics of the study population was summarized in Table 1 . 19) . The coverage of target region was more than 99% in each sample, and the fraction of effective sequence on target region was over 92% in all the reads. The detailed information of exome capture in each sample was summarized in Table 2 . The average sequencing depth of the target region was over 100X among twenty of the samples (Fig. 1) . 
Among the 11 pairs tissues specimens, a total of 299 SNVs in 75 genes were identified. LOH (Loss of heterozygosity) represents a common event in tumorigenesis. In this study, 33 mutations caused by LOH were identified. We found that nonsynonymous SNV was the major reason for LOH among the detected samples (Fig. 2) .
In addition, we also investigated the distribution of nonsynonymous SNV type in the sequencing samples. The most common base pair substitutions was T:A>C:G, accounting for 49.83%, followed by C:G>T:A (18.06%) and C:G>G:C (15.05%) (Fig. 3) .
Driver gene mutations and enriched biological pathways analyses in PTC
A total 75 altered genes including 11 commonly altered genes and 64 novel driver genes were identified in the current study. The most commonly altered genes included the oncogenes PET/PTC1, PET/PTC3, TRK (TRM3/NTRK1), TRK-T3 (TFG/NTRK1), BRAF, Ras, PPFP, and β-Catenin, as well as the tumor suppressor p53. The enriched biological processes analyses were performed based on the identified somatic mutations. According to KEGG Fig. 3 . The distribution of base pair substitutions in each case. There were six patterns of base pair substitutions among the identified SNVs, the most common base pair substitutions was T:A>C:G, accounting for 49.83%, followed by C:G>T:A (18.06%) and C:G>G:C (15.05%). analyses, the mutated genes were mainly implicated in MAPK (mitogen-activated protein kinase), PPAR (peroxisome proliferator-activated receptors), and p53 signaling pathways, suggesting the functional roles of these pathways in the pathology of PTC (Fig. 4) .
Driver gene mutations verified by direct Sanger sequencing
The novel identified driver genes and their mutation types in the 11 pairs tissues specimens were shown in Fig. 5 . In addition, 12 of the mutational genes including FAM133A, DPCR1, GPRASP1, C10orf10, POLR2D, C4orf3, N4BP2L1, PCMTD2, CCBE1, EPB41L3, JAK1, IWS1 were verified by direct Sanger sequencing method. Among them, the mutations of FAM133A, DPCR1, JAK1, C10orf10, EPB41L3, GPRASP1, and IWS1 exhibited in multiple thyroid cancer specimens. Furthermore, the genes might present distinct alterations in different tissues specimens. For instance, in R17 case, FAM133A exhibited a mutation of G>A at the position of 92964956, while in R16 case a substitution of A>C at the position of 92964970 was observed in the gene. The detailed information of individuals mutations of the 12 genes in the 11 tissues specimens were summarized in Table 3 .
Discussion
PTC,
arising from follicular epithelium, represents the major histological type of thyroid cancer [22] . Surgical strategy and radioiodine are accepted as the first-line treatment for patients with PTC, contributing to improved quality of life and prolonged survival time [23] . However, there are still a few of patients will develop recurrence and metastasis, leading to therapeutic failures and dismal outcomes [24] . The heterogenous biological behaviors of PTC may be attributed to the diverse genetic backgrounds and molecular mutations [25] . With the development of sequencing technique, WES can identify the mutational genes and signal pathways during tumorigenesis, which may provide 
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a new way to investigate the molecular pathogenesis of PTC. For example, in the study of Siraj AK et al., they suggested a previously unknown role of thyroglobulin (TG) somatic mutations in the pathogenesis of PTC [26] . Pan et al. found a exome mutational spectrum of PTC in the Chinese population and highlights lncRNA GAS8-AS1 and LPAR4 as potential diagnostic and therapeutic targets [27] . In the current study, we performed WES technology on 11 pairs PTC tissues samples to investigate the somatic variations during tumorigenesis of PTC. Analysis results revealed that multiple protein-coding related mutations were involved in the development and progression of PTC. Moreover, the mutational signature was distinct in each case. In addition to the frequently mutational genes such as PET/PTC1, PET/PTC3, TRK, TRK-T3 (TFG/NTRK1), BRAF, Ras, PPFP, and β-Catenin, 64 novel altered genes were also observed in the present study, suggesting their potential function in progression of the malignant disease.
In this study, we found that the base pair substitutions presented six patterns in PTC cases, including C:G>A:T, C:G>G:C, C:G>T:A, T:A>A:T, T:A>C:G, T:A>G:C, and the most common patterns was T:A>C:G, followed by C:G>T:A and C:G>G:C. Agrawal et al. found that C:G>T:A was the most commonly observed pattern of base pair substitutions in patients with medullary thyroid cancer (MTC) via WES method [28] . The different patterns of base pair substitutions might be responsible for the diverse histological features between PTC and MTC. However, a study based on the WES results of 91 pairs of PTC samples demonstrated that C>T/G>A substitution was the most common pattern in somatic mutations [29] . Several reasons might contribute to the discrepancy, such as the relatively small sample size, the differences between the study population, and the differences between the WES protocols and the analysis methods. Further researches were required to address the issues.
Development and progression of PTC are considered to be the results of the accumulation of genetic and epigenetic alterations. BRAF is the most common mutation in PTC, and its variations may active the MAPK signal pathway, thus promoting the aggressive progression of PTC [30] . It was reported that the prevalence of BRAF mutations was 30-80% [31] . In the present study, the mutations of BRAF gene were observed in 54.54% PTC cases. In addition, the common cancer-related oncogenes such as PET/PTC1, PET/PTC3, TRK (TRM3/NTRK1), TRK-T3 (TFG/NTRK1), BRAF, Ras, PPFP, β-Catenin and the tumor suppressor p53 also exhibited mutations in PTC cases. Moreover, enriched biological process based on the observed somatic variations demonstrated that the altered genes mainly influenced MAPK, PPAR, and p53 signal pathways. The mentioned three signal pathways played important roles in regulation of cell proliferation, cell cycle, and apoptosis. The function of MAPK and p53 signal pathways in progression of PTC had been reported in a variety of studies [32] [33] [34] . It was reported that the activation of MAPK was the primary mechanism for initiation of PTC [20] . The function of PPAR pathway was rarely reported in PTC. PPAR pathway was composed by a group of nuclear receptors which played pivotal roles in cellular differentiation, development and lipid metabolism [35] . The abnormal activation of the signal way implicated with tumorigenesis of bladder cancer, esophageal cancer, follicular thyroid cancers, etc [36] [37] [38] . In this study, we found that PPAR signal pathway was involved in the progression of PTC. The results might demonstrated that the frequently mutated signal pathway in other types of cancer might also take part in the carcinogenesis of PTC.
Driver genes can facilitate aggressive growth and metastasis of malignancies. Identification of novel cancer-related driver genes may provide new targets for treatments of cancers. In this study, besides the commonly observed driver genes, a total of 64 novel driver genes were also observed. Sanger sequencing method was applied to identify 12 of the the novel identified somatic mutations, including FAM133A, DPCR1, GPRASP1, C10orf10, POLR2D, C4orf3, N4BP2L1, PCMTD2, CCBE1, EPB41L3, JAK1, IWS1. The mutations of FAM133A, DPCR1, JAK1, C10orf10, EPB41L3, GPRASP1, and IWS1 were observed in multiple cases, even the same genes might present diverse mutational status in different cases. The results might explain the individuals differences in PTC patients, and the related genes held the potential to serve as targets for individuals treatments. In the previous studies, a number of potential driver genes were also found in other subtypes of thyroid cancer through [40] . The different mutational profiles of driver genes between the subtypes of thyroid cancer might explain the heterogeneity of thyroid cancer, as well as the individual differences. Therefore, application of direct Sanger sequencing technology in more samples could provide new insight into the heterogeneity of malignancy that might contribute to the individual treatments. Despite of the encouraging results obtained in our study, there were still several limitations. Firstly, due to the limited study time, the sample size in our study was relatively small that might cause bias to the final results. Second, in this study we only compared the mutational patterns between PTC tissues and non-cancerous samples, however, the driver genes associated with grade or metastasis of PTC were not explored. Third, in our study, we only identify PTC-related driven genes, but their functional roles as well as the corresponding molecular mechanisms remained unclear. Further investigations with a larger sample size will be required to address the issues.
In conclusion, WES combined with direct Sanger sequencing method may be a promising approach to investigate the mutational landscape during tumorigenesis of PTC. The enriched biological processes analyses based on the identified altered genes suggest that MAPK, PPAR, and p53 signal pathways are implicated in development and progression of PTC. The mutational signature of the novel identified genes is distinct in each case which may have the ability to serve as targets for individual treatments in PTC patients.
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